A U.S. Food and Drug Administration (FDA) advisory committee has reviewed Johnson & Johnson's (NYSE: JNJ) data supporting boosters of its COVID-19 vaccine. The FDA gets the final say in the matter, though. In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss J&J's prospects for authorization of boosters.
For the first time in over 10 months, the stock market is showing signs of fatigue. It's a drop in the bucket compared to the index's gains since the March 2020 bear-market bottom, but it's a potentially stern reminder that a stock market crash or double-digit correction could be around the corner. According to data from market analytics company Yardeni Research, there have been only three instances since the beginning of 1995 where margin debt jumped 60% or more in a single year.
The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporting docket.